What's Happening?
Calico Life Sciences LLC, a biotechnology company focused on aging and age-related diseases, has appointed Philip R. Kym, Ph.D., as its Head of Drug Discovery. Dr. Kym will be responsible for overseeing
the scientific execution and operational management of Calico's drug discovery programs. His role will involve guiding the process from target identification to candidate selection. Dr. Kym brings nearly three decades of experience in the biopharmaceutical industry, having previously served as Vice President of Global Medicinal Chemistry at AbbVie. His expertise spans various therapeutic areas, including antiviral, oncology, and neuroscience. Dr. Kym's appointment is expected to bolster Calico's efforts in advancing its portfolio and collaborations aimed at developing new medicines targeting aging and age-related diseases.
Why It's Important?
The appointment of Dr. Kym is significant as it underscores Calico's commitment to advancing research in aging and age-related diseases. With an aging population, the demand for innovative treatments in this area is growing. Dr. Kym's extensive experience in medicinal chemistry and his leadership in drug discovery are expected to enhance Calico's capabilities in developing first-in-class medicines. This move could potentially lead to breakthroughs in extending human healthspan, benefiting society by improving quality of life for the elderly. Additionally, Calico's focus on integrating AI and machine learning into drug discovery could position it at the forefront of biopharmaceutical innovation.
